Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy
- Status
- UNKNOWN
- Phase
- PHASE2
Clinical Trials Related to Ruxolitinib
Related studies linked through entity extraction aliases.
Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations.
- Status
- TERMINATED
- Phase
- PHASE3
Pharmacodynamic Effects and Predictive Biomarkers With Ruxolitinib in Operable Head and Neck Cancer
- Status
- WITHDRAWN
- Phase
- EARLY_PHASE1
A Study to Evaluate the Efficacy and Safety of Vismodegib in Combination With Ruxolitinib for the Treatment of Intermediate- or High-Risk Myelofibrosis (MF)
- Status
- COMPLETED
- Phase
- PHASE1
Study of INCB053914 in Subjects With Advanced Malignancies
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea
- Status
- COMPLETED
- Phase
- PHASE1
Evaluating the Safety and Tolerability of Ruxolitinib in Antiretroviral-Treated HIV-Infected Adults
- Status
- COMPLETED
- Phase
- PHASE2
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease
- Status
- TERMINATED
- Phase
- PHASE1
A Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome
- Status
- COMPLETED
- Phase
- PHASE2
CINC424A2X01B Rollover Protocol
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE4
Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With Myelofibrosis
- Status
- COMPLETED
- Phase
- PHASE1
Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.
- Status
- COMPLETED
- Phase
- PHASE3
Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)
- Status
- COMPLETED
- Phase
- PHASE2
Safety and Tolerability of Combined Treatment With Nilotinib and Ruxolitinib in CML and Ph+ ALL Patients
- Status
- COMPLETED
- Phase
- PHASE1
JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis
- Status
- COMPLETED
- Phase
- PHASE2
JAK-inhibition in Recurrent Classical Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2